Search

Displaying results 431 - 440 of 10000 in total
  1. Drug

    6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE

    go.drugbank.com/drugs/DB07704
    Experimental

    Synonyms: 6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE
  2. Drug

    AB-22

    go.drugbank.com/drugs/DB18296
    Experimental

    Synonyms: Hydrazinecarboxamide, n-(2-chloro-6-propoxy-4-pyridinyl)-2-(1,3-dimethyl-4-(1-methylethyl)-1h-pyrazolo(3,4-b)pyridin-6-yl)-2-(2-hydroxyethyl)-, N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1h-pyrazolo(3,4-b)pyridin-6-yl)hydrazinecarboxamide
  3. Drug

    Naporafenib

    go.drugbank.com/drugs/DB18865
    Investigational

    Naporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-pyridinecarboxamide, n-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-, N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide
  4. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE
  5. Drug

    N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide

    go.drugbank.com/drugs/DB07175
    Experimental

    Synonyms: N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide
  6. Drug

    S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE

    go.drugbank.com/drugs/DB07602
    Experimental

    Synonyms: S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  7. Drug

    6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE

    go.drugbank.com/drugs/DB07612
    Experimental

    Synonyms: 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  8. Drug

    Folic acid

    go.drugbank.com/drugs/DB00158
    ApprovedInvestigationalNutraceuticalVet approved

    As a result, supplementation with 1-5mg of folic acid is recommended to prevent deficiency and a number of side effects associated with MTX therapy including mouth ulcers and gastrointestinal irritation … Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis.

    Mixtures: Vitamin C 202,8 mg/0,8 mg/100 mg - Hartkapseln, SIN SED POLVO (PARA BEBIDA HIDRATANTE VITAMINADA)Categories: Vitamin B Complex, Heterocyclic Compounds, 2-Ring
  9. Drug

    TSN-084

    go.drugbank.com/drugs/DB18306
    Investigational

    Synonyms: 3-PYRIDINECARBOXAMIDE, N-(3-FLUORO-4-((1-METHYL-6-(1H-PYRAZOL-4-YL)-1H-INDAZOL-5-YL)OXY)PHENYL)-1-(4-FLUOROPHENYL)-1,2-DIHYDRO-6-(1-METHYLETHOXY)-2-OXO-, N-[3-fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-(1-methylethoxy)-2-oxo-3-pyridinecarboxamide
  10. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide